Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this experimental study, human SSCs were isolated and their identities were confirmed by tracking their promyelocytic leukemia zinc finger (PLZF) protein.
|
30123997 |
2019 |
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
With RT-PCR and karyotype, Case A is diagnosed with STAT5b-RARα-positive APL.Case B, C are diagnosed with PLZF-RARα-positive APL.
|
31083206 |
2019 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, we for the first time report that phenylarsine oxide (PAO) could effectively induce PLZF-RARα variant fusion protein degradation through ubiquitin proteasome degradation pathway by apoptosis, which indicates that PAO might be a potential candidate for the treatment of PLZF-RARα variant APL.
|
30869512 |
2019 |
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, under steady-state conditions, DP T cells expressed eomesodermin (Eomes) and promyelocytic leukemia zinc finger (PLZF) proteins, both of which act as transcription factors in innate/memory-like T cells.
|
30116750 |
2018 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
CDC: Centers for Disease Control; DMSO: dimethyl sulfoxide; GHR: growth hormone receptor; hESCs: human embryonic stem cells; PFASs: per- and polyfluoroalkyl substances; PFCs: perfluorinated compounds; PFNA: perfluorononanoic acid; PFOS: perfluorooctanesulfonic acid; PFOA: perfluorooctanoic acid; PLZF: promyelocytic leukemia zinc finger; ROS: reactive oxygen species; HILI: RNA-mediated gene silencing 2; SSC: spermatogonial stem cell.
|
29911897 |
2018 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, EYA2 may be a target for molecular therapy in this subtype of AML, including <i>PLZF-RARA</i> APL.
|
28416638 |
2017 |
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Moreover, patients with APL carrying the PLZF-RARα fusion protein are partially resistant to ATRA treatment.
|
25931453 |
2015 |
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The transcriptions of the proapoptotic genes, insulin-like growth factor binding protein 3 (IGFBP3) and BCL2-interacting killer (BIK), were suppressed by ZNF179 via its interaction with the promyelocytic leukemia zinc finger (PLZF) protein in astrocytes.
|
24788683 |
2015 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The variant t(11;17) translocation produces two fusion proteins, promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα) and RARα-PLZF, both of which participate in leukemia development.
|
23898169 |
2013 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
By using a murine leukemic model carrying both promyelocytic leukemia zinc finger/retinoic acid receptor-α (PLZF/RARα) and RARα/PLZF fusion genes, we discovered that 8-chlorophenylthio adenosine-3', 5'-cyclic monophosphate (8-CPT-cAMP) enhances cellular differentiation and improves gene trans-activation by ATRA in leukemic blasts.
|
23382200 |
2013 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
CTD_human |
Acute promyelocytic leukemia (APL) is predominantly characterized by chromosomal translocations between the retinoic acid receptor, alpha (RARA) gene and the promyelocytic leukemia (PML) or promyelocytic leukemia zinc finger (PLZF) gene.
|
23208507 |
2013 |
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is predominantly characterized by chromosomal translocations between the retinoic acid receptor, alpha (RARA) gene and the promyelocytic leukemia (PML) or promyelocytic leukemia zinc finger (PLZF) gene.
|
23208507 |
2013 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
This paper describes two cases of APL associated with the PLZF-RARA fusion gene enrolled in the IC-APL trial that is a non-randomized, multicenter study conducted in Brazil, Mexico, Chile and Uruguay with the aim to improve the treatment outcome of APL patients in developing countries.
|
22205181 |
2012 |
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The PLZF/RARA fusion protein generated by the t(11;17)(q23;q21) translocation in acute promyelocytic leukaemia (APL) is believed to act as an oncogenic transcriptional regulator recruiting epigenetic factors to genes important for its transforming potential.
|
21949697 |
2011 |
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The promyelocytic leukemia zinc finger (PLZF) protein exerts neuroprotective effects in neuronal cells and is dysregulated in experimental stroke.
|
20731660 |
2011 |
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The t(11;17)(q23;q21) translocation is associated with a retinoic acid (RA)-insensitive form of acute promyelocytic leukemia (APL), involving the production of reciprocal fusion proteins, promyelocytic leukemia zinc finger-retinoic acid receptor alpha (PLZF-RARalpha) and RARalpha-PLZF.
|
19855079 |
2009 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The PLZF gene is one of five partners fused to the retinoic acid receptor alpha in acute promyelocytic leukaemia.
|
18611983 |
2008 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Retinoic acid treatment of mouse APLs expressing the fusion protein PLZF-RARA triggers full differentiation, but not LIC loss or disease remission, establishing that differentiation and LIC loss can be uncoupled.
|
19029980 |
2008 |
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In line with these observations, RA-resistant murine PLZF/RARalpha+RARalpha/PLZF APL blasts express much higher levels of CRABPI than standard RA-sensitive PML/RARalpha APL.
|
18000064 |
2007 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The PLZF gene is one of five partners fused to the retinoic acid receptor alpha in acute promyelocytic leukemia.
|
17217037 |
2007 |
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To determine whether the promyelocytic leukemia zinc finger (PLZF) protein, a transcriptional repressor and negative regulator during cell cycling, plays a role in the proliferation of cultured human corneal endothelial cells (HCECs).
|
17515885 |
2007 |
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.
|
17194664 |
2006 |
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combination chemotherapy can achieve sustained remission in patients with PLZF/RARalpha APML.
|
15592671 |
2005 |
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
As an approach to silencing estrogen-regulated genes, we have studied the activities of a fusion protein between ERalpha and the promyelocytic leukemia zinc-finger (PLZF) protein, a transcriptional repressor that acts through chromatin remodeling.
|
15647773 |
2005 |
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This phenotype is induced by specific acute myeloid leukemia-associated translocations, such as t(15;17) and t(11;17), which involve an identical portion of the retinoic acid receptor alpha (RARalpha) and either the promyelocytic leukemia (PML) or promyelocytic zinc finger (PLZF) genes, respectively.
|
16024608 |
2005 |